In HER2+/PIK3CA mutated breast cancer cell lines, alpelisib was more potent than trastuzumab or trastuzumab + pertuzumab in inhibiting the in vitro growth and the combination of alpelisib plus trastuzumab also showed synergistic activity. Here, PIK3CA is linked to breast carcinoma.